Contact
We scope to your needs—single targets, portfolios, or disease-centric scans—with a fixed proposal and delivery timeline. Every deliverable is grounded in the Open Targets Platform, so narratives are traceable and updatable as data changes.
Pricing that fits the boardroom
We structure engagements so decision makers get predictable spend, clear deliverables, and no scope creep. No hourly surprises or open-ended SOWs—you approve a fixed scope, price, and timeline up front. Ideal for budget planning, procurement, and internal sign-off in pharma and biotech.
- Fixed-fee, fixed-timeline — Agreed price and delivery date before work starts.
- Entity-based scoping — Price and effort scale transparently with the number of targets, diseases, or drugs you choose.
- Portfolio and program options — Multi-project or ongoing monitoring can be quoted as a single engagement for easier approval and reporting.
- Evidence you can stand behind — All outputs traceable to the Open Targets Platform; suitable for internal governance and external partners.
How we scope
Fees and timeline are determined by the entities you specify and the depth of analysis. Every deliverable is traceable to the Platform evidence.
| Entity type | What we scope | Typical use |
|---|---|---|
| Target | Per target (e.g. Ensembl ID) | Single target assessment, due diligence |
| Disease / indication | Per disease or indication set (e.g. EFO ID) | Indication prioritisation, disease-centric landscape |
| Drug | Per drug or drug set | Competitive or mechanism context, repurposing scan |
| Portfolio | N targets and/or N diseases | Pipeline or portfolio review, multi-target due diligence |
You get a fixed price and timeline up front—no surprises.
Get in touch
Email: john@bioticabio.com
Next step
A short call to align on entities and depth, then a written proposal with price and timeline.
Before reaching out, you can review an example deliverable and the methodology used in every assessment.
If helpful for internal context, include links to operator background or a relevant decision framework in your note.
Disclaimer
Our assessments are for strategic and due-diligence use only; they do not constitute regulatory, medical, or investment advice.
We use your contact details only to respond and do not share them with third parties.